BC
CTMX icon

BIT Capital’s CytomX Therapeutics CTMX Stock Holding History

BIT Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-16,285
Closed -$51.9K – 118
2025
Q3 		$51.9K Buy
+16,285
New +$36.7K ﹤0.01% 105
2024
Q2 		– Sell
-250,910
Closed -$547K – 111
2024
Q1 		$547K Buy
+250,910
New +$463K 0.04% 102

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

BIT Capital's CTMX Position: Q4 2025 in Review

BIT Capital sold out of CytomX Therapeutics (CTMX) in Q4 2025, closing a stake of 16,285 shares — an estimated $51.9K sold.

BIT Capital first reported a position in CTMX in Q1 2024 and held it in 2 quarters. The position peaked at $547K in Q1 2024. 122 funds tracked by Wall St. Rank hold CTMX as of Q4 2025.

  • BIT Capital reported no remaining CytomX Therapeutics position as of Q4 2025 after selling out during the quarter.
  • BIT Capital sold 16,285 CytomX Therapeutics shares in Q4 2025, an estimated $51.9K.
  • BIT Capital first reported a position in CytomX Therapeutics in Q1 2024 and held it in 2 quarters.
  • BIT Capital's CytomX Therapeutics position peaked at $547K in Q1 2024.
  • 122 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q4 2025.

Based on BIT Capital's 13F filing for Q4 2025, filed 11 Feb 2026.